Gilead Sciences, Inc.
NEWS
It’s no secret that the life sciences are increasingly international.
Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.
There are hundreds, even thousands of biotech and pharmaceutical companies.
Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.
CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
Gilead Sciences’ third-quarter financial results were dismal, to say the least.
CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.
Gilead continues to see serious revenue declines in its hepatitis C marketshare, a space it has dominated for several years.
JOBS
IN THE PRESS